224 related articles for article (PubMed ID: 28662189)
1. Affective and cognitive behavior in the alpha-galactosidase A deficient mouse model of Fabry disease.
Hofmann L; Karl F; Sommer C; Üçeyler N
PLoS One; 2017; 12(6):e0180601. PubMed ID: 28662189
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive and differential long-term characterization of the alpha-galactosidase A deficient mouse model of Fabry disease focusing on the sensory system and pain development.
Üçeyler N; Biko L; Hose D; Hofmann L; Sommer C
Mol Pain; 2016; 12():. PubMed ID: 27145802
[TBL] [Abstract][Full Text] [Related]
3. Dysregulation of Immune Response Mediators and Pain-Related Ion Channels Is Associated with Pain-like Behavior in the GLA KO Mouse Model of Fabry Disease.
Spitzel M; Wagner E; Breyer M; Henniger D; Bayin M; Hofmann L; Mauceri D; Sommer C; Üçeyler N
Cells; 2022 May; 11(11):. PubMed ID: 35681422
[TBL] [Abstract][Full Text] [Related]
4. Mood and memory-associated behaviors in neuropeptide Y5 knockout mice.
Ito M; Dumont Y; Quirion R
Neuropeptides; 2013 Apr; 47(2):75-84. PubMed ID: 23218957
[TBL] [Abstract][Full Text] [Related]
5. α-Galactosidase A knockout mice: progressive organ pathology resembles the type 2 later-onset phenotype of Fabry disease.
Bangari DS; Ashe KM; Desnick RJ; Maloney C; Lydon J; Piepenhagen P; Budman E; Leonard JP; Cheng SH; Marshall J; Thurberg BL
Am J Pathol; 2015 Mar; 185(3):651-65. PubMed ID: 25553976
[TBL] [Abstract][Full Text] [Related]
6. Characterization of small fiber pathology in a mouse model of Fabry disease.
Hofmann L; Hose D; Grießhammer A; Blum R; Döring F; Dib-Hajj S; Waxman S; Sommer C; Wischmeyer E; Üçeyler N
Elife; 2018 Oct; 7():. PubMed ID: 30328411
[TBL] [Abstract][Full Text] [Related]
7. Affective and cognitive behavior is not altered by chronic constriction injury in B7-H1 deficient and wildtype mice.
Karl F; Colaço MBN; Schulte A; Sommer C; Üçeyler N
BMC Neurosci; 2019 Apr; 20(1):16. PubMed ID: 30975083
[TBL] [Abstract][Full Text] [Related]
8. Transgenic mouse expressing human mutant alpha-galactosidase A in an endogenous enzyme deficient background: a biochemical animal model for studying active-site specific chaperone therapy for Fabry disease.
Ishii S; Yoshioka H; Mannen K; Kulkarni AB; Fan JQ
Biochim Biophys Acta; 2004 Nov; 1690(3):250-7. PubMed ID: 15511632
[TBL] [Abstract][Full Text] [Related]
9. Systemic mRNA Therapy for the Treatment of Fabry Disease: Preclinical Studies in Wild-Type Mice, Fabry Mouse Model, and Wild-Type Non-human Primates.
Zhu X; Yin L; Theisen M; Zhuo J; Siddiqui S; Levy B; Presnyak V; Frassetto A; Milton J; Salerno T; Benenato KE; Milano J; Lynn A; Sabnis S; Burke K; Besin G; Lukacs CM; Guey LT; Finn PF; Martini PGV
Am J Hum Genet; 2019 Apr; 104(4):625-637. PubMed ID: 30879639
[TBL] [Abstract][Full Text] [Related]
10. Increased globotriaosylceramide levels in a transgenic mouse expressing human alpha1,4-galactosyltransferase and a mouse model for treating Fabry disease.
Shiozuka C; Taguchi A; Matsuda J; Noguchi Y; Kunieda T; Uchio-Yamada K; Yoshioka H; Hamanaka R; Yano S; Yokoyama S; Mannen K; Kulkarni AB; Furukawa K; Ishii S
J Biochem; 2011 Feb; 149(2):161-70. PubMed ID: 20961863
[TBL] [Abstract][Full Text] [Related]
11. Partial correction of the alpha-galactosidase A deficiency and reduction of glycolipid storage in Fabry mice using synthetic vectors.
Przybylska M; Wu IH; Zhao H; Ziegler RJ; Tousignant JD; Desnick RJ; Scheule RK; Cheng SH; Yew NS
J Gene Med; 2004 Jan; 6(1):85-92. PubMed ID: 14716680
[TBL] [Abstract][Full Text] [Related]
12. Reduced glucosylceramide in the mouse model of Fabry disease: correction by successful enzyme replacement therapy.
Quinta R; Rodrigues D; Assunção M; Macedo MF; Azevedo O; Cunha D; Oliveira P; Sá Miranda MC
Gene; 2014 Feb; 536(1):97-104. PubMed ID: 24334116
[TBL] [Abstract][Full Text] [Related]
13. Therapeutic Strategy for Fabry Disease by Intravenous Administration of Adeno-Associated Virus 9 in a Symptomatic Mouse Model.
Hayashi Y; Sehara Y; Watano R; Ohba K; Takayanagi Y; Sakiyama Y; Muramatsu K; Mizukami H
Hum Gene Ther; 2024 Mar; 35(5-6):192-201. PubMed ID: 38386497
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic strategy for Fabry disease by intravenous administration of adeno-associated virus 2 or 9 in α-galactosidase A-deficient mice.
Hayashi Y; Sehara Y; Watano R; Ohba K; Takayanagi Y; Muramatsu K; Sakiyama Y; Mizukami H
J Gene Med; 2023 Dec; 25(12):e3560. PubMed ID: 37392007
[TBL] [Abstract][Full Text] [Related]
15. Endothelial Cell Dysfunction and Hypoxia as Potential Mediators of Pain in Fabry Disease: A Human-Murine Translational Approach.
Klug K; Spitzel M; Hans C; Klein A; Schottmann NM; Erbacher C; Üçeyler N
Int J Mol Sci; 2023 Oct; 24(20):. PubMed ID: 37895103
[TBL] [Abstract][Full Text] [Related]
16. Increased anxiety-related behaviour in Hint1 knockout mice.
Varadarajulu J; Lebar M; Krishnamoorthy G; Habelt S; Lu J; Bernard Weinstein I; Li H; Holsboer F; Turck CW; Touma C
Behav Brain Res; 2011 Jul; 220(2):305-11. PubMed ID: 21316396
[TBL] [Abstract][Full Text] [Related]
17. IL-6 deficiency alters spatial memory in 4- and 24-month-old mice.
Bialuk I; Taranta A; Winnicka MM
Neurobiol Learn Mem; 2018 Nov; 155():21-29. PubMed ID: 29908286
[TBL] [Abstract][Full Text] [Related]
18. Distributions of Globotriaosylceramide Isoforms, and Globotriaosylsphingosine and Its Analogues in an α-Galactosidase A Knockout Mouse, a Model of Fabry Disease.
Sueoka H; Aoki M; Tsukimura T; Togawa T; Sakuraba H
PLoS One; 2015; 10(12):e0144958. PubMed ID: 26661087
[TBL] [Abstract][Full Text] [Related]
19. Long-term enzyme correction and lipid reduction in multiple organs of primary and secondary transplanted Fabry mice receiving transduced bone marrow cells.
Takenaka T; Murray GJ; Qin G; Quirk JM; Ohshima T; Qasba P; Clark K; Kulkarni AB; Brady RO; Medin JA
Proc Natl Acad Sci U S A; 2000 Jun; 97(13):7515-20. PubMed ID: 10840053
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive behavioral phenotyping of a new Semaphorin 3 F mutant mouse.
Matsuda I; Shoji H; Yamasaki N; Miyakawa T; Aiba A
Mol Brain; 2016 Feb; 9():15. PubMed ID: 26856818
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
